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pression	of	BLVRA	but	also	in	four	most	common	Drosophila PD models. Furthermore, 
down-regulation	of	SMARCA4	specifically	 in	 the	dopaminergic	neurons	prevented	
shortening of life span caused by α-synuclein	and	LRRK2.	Mechanistically,	aberrant	
SMARCA4	and	BLVRA	converged	on	elevated	ERK-ETS	activity,	attenuation	of	which	
by either genetic or pharmacological manipulation effectively suppressed dopamin-
ergic degeneration in Drosophila	in	vivo.	Down-regulation	of	SMARCA4	or	drug	inhi-
bition of MEK/ERK also mitigated mitochondrial defects in PINK1	(a	PD-associated	
gene)-deficient	human	cells.	Our	 findings	underscore	 the	 important	 role	of	epige-
netic	regulators	and	implicate	a	common	signaling	axis	for	therapeutic	intervention	in	
normal	aging	and	a	broad	range	of	age-related	disorders	including	PD.
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1  | INTRODUC TION
Among	 age-related	 diseases,	 Parkinson's	 disease	 (PD)	 is	 the	most	
common neurodegenerative movement disorder, with an incidence 
rate	above	1%	among	individuals	over	65	years	of	age	(Nalls	et	al.,	
2014).	 The	 pathologic	 manifestations	 of	 PD	 include	 age-depen-
dent	progressive	dopaminergic	(DA)	neuronal	deterioration	in	basal	
ganglia and substantia nigra, with reduction of dopamine release. 
Remarkable	 similarities	 at	 the	 molecular	 and	 cellular	 levels	 exist	
between PD and normal aging. Current treatments for PD are only 
symptomatic, ameliorating disease symptoms for a limited period of 
time, without retarding or halting disease progression.
Parkinson's	disease	is	a	complex	disease	with	high	heterogeneity.	
Etiologically,	PD	consists	of	early-onset	subtypes,	which	are	primar-
ily due to high penetrance mutations and familial inheritance, and 
late-onset	subtypes,	which	occur	more	sporadically	and	are	believed	
to	result	from	complex	interactions	between	genetic,	environmental	
factors superimposed on the physiological decline of neuronal func-
tions with age. Emerging evidence affirms the central role of genetic 
susceptibility	 in	PD	(Lill	et	al.,	2012;	Nalls	et	al.,	2014).	Although	a	
comprehensive genetic architecture corresponding to distinct PD 
subtypes remains poorly understood, the same set of susceptibility 
genes	may	 predispose	 people	 to	 both	 familial	 and	 sporadic	 PD.	A	
number of causal genetic risk factors have been linked to PD onset, 
including mutations in SNCA (α-synuclein),	 LRRK2	 (leucine-rich	 re-
peat	kinase	2),	VPS35	(the	vacuolar	sorting	protein	35	gene),	EIF4G1 
(eukaryotic	 translation	 initiation	 factor	 4-gamma)	 and	 DNAJC13 
[DnaJ	heat	shock	protein	family	 (Hsp40)	member	C13]	genes	with	
autosomal dominant inheritance mode, and PARK2	 (parkin),	PINK1 
(PTEN	induced	putative	kinase	1),	PARK7 (Parkinsonism associated 
deglycase, DJ1),	HTRA2	(high	temperature	requirement	A2),	DNAJC6	
[DnaJ	 heat	 shock	 protein	 family	 (Hsp40)	 member	 C6],	 FBXO7	 (F-
box	 domain-containing	 protein),	PLA2G6	 (phospholipase	A2	 group	
VI),	SYNJ1	 (synaptojanin	1),	ATP6AP2	 (ATPase	H+ transporting ac-
cessory	protein	2)	and	ATP13A2	(ATPase	type	13A2)	with	recessive	
inheritance	mode	(Lin	&	Farrer,	2014).
Typically, these known PD genes participate in diverse cellular 
processes; however, common themes in PD pathogenesis have been 
proposed, such as aberrant proteostasis and vesicle trafficking, mi-
tochondrial dysfunction, altered epigenetic regulation, and inflam-
mation	 (Coppedè,	 2013).	 Notably,	 all	 these	 involved	 pathogenic	
agents are similar to those in normal aging. Therefore, the insights 
involved in PD pathogenesis may be critical for understanding and 
modifying aging, and vice versa. Nevertheless, the majority of PD 
heritable components remain elusive (Lill et al., 2012; Nalls et al., 
2014).	How	to	extract	contributing	factors	from	limited	human	brain	
specimens is the main challenge to solve this heterogeneous disease, 
because only postmortem human brain specimens can be available. 
More challengingly, most postulated novel genetic associations or 
risk factors await further validation.
Gene	co-expression	analysis	allows	identifying	genes	with	similar	
expression	patterns	across	a	set	of	samples,	which	has	facilitated	iden-
tifying genes involved in certain disease pathways, new gene functions, 
and	potential	biomarkers	(Zhang	et	al.,	2012).	In	this	study,	we	used	the	
known PD genes as “anchors” in order to identify new PD candidate 
genes	that	are	highly	co-expressed	with	known	PD	genes	with	multiple	
human	brain	microarray	datasets.	Among	the	predicted	32	candidate	
genes,	 SWI/SNF-related,	 matrix-associated,	 actin-dependent	 regu-
lator	of	chromatin,	subfamily	A,	member	4	(SMARCA4)	and	biliverdin	
reductase	 A	 (BLVRA)	 were	 further	 studied	 in	 vivo	 using	Drosophila 
melanogaster, and their potential involvement in PD pathogenesis was 
confirmed.	 Furthermore,	we	 revealed	 a	 potential	 common	 aging-re-
lated	 pathogenic	 signaling	 pathway	 consisting	 of	 the	 chromatin-re-
modeling	factor	SMARCA4	and	the	ERK-ETS	signaling	axis,	suggesting	
new	therapeutic	targets	for	PD	and	other	aging-related	disorders,	as	
three	 ERK-ETS	 inhibitors	 were	 tested	 for	 their	 efficacy	 in	 multiple	





2.1 | Gene co-expression network analysis 
identified 32 novel PD-associated candidate genes
We	chose	seven	of	the	most	commonly	known	PD	genes	as	anchor	
genes, namely SCNA, LRRK2, PARKIN, DJ1, PINK1, ATP13A2, and 
HTR2A.	Eleven	datasets	from	NCBI	Gene	Expression	Omnibus	(GEO)	
were used, which contained samples from human brain tissues, es-







2.2 | Inhibition of Brahma rescued progressive 
DA degeneration caused by overexpression of BVR 
in Drosophila
Among	 the	 32	 candidate	 genes,	we	 chose	 SMARCA4	 and	BLVRA	
(biliverdin	reductase	A)	for	further	studies	based	on	the	rationales	
K E Y W O R D S
aging, Drosophila,	MAPK-ERK-ETS	signaling,	neurodegeneration,	Parkinson's	disease,	
SMARCA4/Brahma
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below	(Table	S2).	First,	according	to	the	Human	Brain	Transcriptome	
(HBT:	 https://hbatl	as.org/pages/	hbtd)	 and	 the	 Allen	 Brain	 Atlas	
(http://human.brain-map.org/),	both	SMARCA4	and	BLVRA	are	ex-
pressed widely in the human brain, including the substantia nigra. 
Second,	 mutations	 of	 SMARCA4/Brm,	 a	 subunit	 of	 the	 SWI/SNF	
chromatin-remodeling	 complex	 that	 regulates	 higher	 order	 chro-
matin	structure	and	gene	expression,	have	been	 linked	to	multiple	
neurological and psychiatric disorders including autism spectrum 




functional	 reports	of	 its	 role	for	DA	neurons	yet.	Biliverdin	reduc-
tases	(BLVRs),	together	with	hemeoxygenases	(HOs),	constitute	the	
evolutionarily	 conserved	 enzymes	 in	 the	 heme	metabolism,	 exert	
multiple physiological functions, and have been considered as a po-
tential	biomarker	for	AD	and	mild	cognitive	impairment	(Barone,	Di	






0.05, which can be regarded as the potential PD risk SNPs albeit 
not	in	the	top	10,000	most	significant	GWAS	results.	Furthermore,	
both	SMARCA4	and	BLVRA	are	highly	conserved	among	vertebrate	
and invertebrate species (Brahma or Brm for Drosophila	SMARCA4	
homologue	and	dBVR	(CG9471)	for	Drosophila	BLVRA	homologue).
F I G U R E  1  Bioinformatics	analyses.	(a)	Overview	of	frequent	gene	co-expression	analysis	in	identifying	novel	Parkinson's	disease-
associated genes. Eleven NCBI GEO DataSets were identified with the microarray datasets of the substantia nigra brain region of human PD 
patients.	Seven	genes	were	used	as	the	anchor	PD	genes.	See	Section	4	for	more	details.	(b)	Ingenuity	Pathway	Analysis	(IPA)	revealed	the	
connection	of	SMARCA4/Brm	with	MAPK	kinase	pathway.	Red	lines	indicate	genes	known	to	interact	with	ERK	signaling.	Solid	line:	direct	
interaction; dash line: indirect interaction; arrows indicate the direction of interaction between two molecules. Different shapes indicate the 
type of the molecules
Anchor gene 
count (N) Gene symbols
5 SMARCA4
4 UBE3A, SNRPN, SLC25A3, PRDX2, GNAS, ARF1, ACTG1
3 VCP, TTC3, STMN2, RNF187, OBSL1, OAZ1, NTRK3, NSFL1C, MAP2 K4, LARP1, 
KLC1, IGHG1, GAPDH, GAP43, EPB41L1, DSTN, DKK3, CLTA, BLVRA, ATP6V1C1, 
ATP5O, ATP5G3, ARF3, AAK1
TA B L E  1   Genes with highest anchor 
gene count (N[•]values)	in	at	least	five	
datasets
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To study the in vivo roles of candidate genes in PD pathogenesis, 
we took advantage of the Drosophila melanogaster model organism. 
The	age-dependent	progressive	DA	neuronal	loss	in	the	lateral	pro-
tocerebral	posterior	1	 (PPL1)	cluster	was	used	as	the	neurodegen-
erative	 index	 (Figure	 2a–b).	We	 then	 used	 an	 available	 Brm::GFP	
reporter	 fly	 strain	 to	examine	whether	Brahma	 is	expressed	 in	 fly	
DA	 neurons	 (Venken	 et	 al.,	 2011).	 Brm::GFP	was	 first	 verified	 by	
its nuclear localization in Drosophila	 larval	 tissues	 (Figure	 S1a–c).	
Whole-mount	 immunostaining	 then	 confirmed	 the	 expression	 of	
Brm	 in	 the	 fly	DA	neurons	 (Figure	 2c),	 consistent	with	 a	 previous	
report	(Abruzzi	et	al.,	2017).
Drosophila genetic manipulations were then carried out to 
dissect	 the	 roles	 of	 Brm	 and	 dBVR.	 When	 Brm	 RNAi-mediated	
down-regulation	 (Herr	 et	 al.,	 2010)	 or	 ectopic	 supply	 of	 a	 dom-
inant-negative	 allele	 of	 Brm	 (BrmDN)	 was	 induced	 specifically	
in	 DA	 neurons,	 no	 change	 in	 the	 number	 of	 PPL1	 DA	 neurons	















2.3 | Brahma was upregulated in multiple Drosophila 
PD models
We	 then	 examined	 how	 Brm	 and	 dBVR	 genetically	 interact	 with	




null alleles were found to be unhealthy in our laboratory, we used 
Parkin	RNA	interference	(RNAi)	flies	instead.	These	four	Drosophila 
PD models were abbreviated as αSyn	 (A30P),	 LRRK2	 (I1915T),	
Parkin,	 Pink1	 (Pink1	mut	 or	 Pink1	 RNAi)	 PD	models,	 respectively	
(see	Section	4	&	fly	genotypes	listed	in	the	Appendix	S2).	Consistent	
with	 previous	 findings,	 age-dependent	 progressive	 degeneration	




By	 labeling	 DA	 neurons	 with	 red	 fluorescent	 protein	 (RFP)	 in	
parallel,	we	found	that	Brm::GFP	level	exhibited	an	age-dependent	
progressive elevation in the PD fly brains compared with controls 
(Figure	2f).	We	next	addressed	how	Brm	 is	upregulated	 in	the	de-
generative dopaminergic neurons. One possibility is there could be 
a	 link	 between	Brm	 activity	 and	 oxidative	 stress,	which	 has	 been	




idant	 response	 in	 the	brains	of	PD	model	 flies	using	GstD-GFP	as	
a	reporter	(Sykiotis	&	Bohmann,	2008)	(Figure	S8).	To	our	surprise,	
unlike	Brm	which	was	pronouncedly	elevated	at	15d	AE	during	the	
disease progression in all four PD models, no substantial increase 
of	brain	oxidative	stress	reporting	signal	was	detected	until	15-20d	




2.4 | Down-regulation of Brahma specifically in the 
DA neurons restored life span in the Drosophila 
PD models




F I G U R E  2   Inhibition	of	Brahma	rescued	dopaminergic	(DA)	degeneration	caused	by	overexpression	of	BVR	in	Drosophila.	(a)	Schematic	
diagram	of	representative	DA	neuronal	clusters	in	adult	Drosophila	brain.	(b)	Representative	images	show	the	posterior	DA	clusters	in	the	fly	





of	wide	type	Brm	(Brm	wt),	a	dominant-negative	allele	of	Brm	(BrmDN),	dBVR	OE	(Bvr	II	and	Bvr	III),	Bvr	II	+ BrmDN and induction of Brm 
RNAi,	BVR	RNAi	or	Bvr	II	+Brm	RNAi	with	w-	(TH-Gal4/+)	and	Luc	RNAi	(TH-Gal4/UAS-Luc	RNAi)	flies	as	the	control.	The	genotypes	
of	experimental	flies	are	provided	in	the	Appendix	S2.	Overexpression	of	dBVR	resulted	in	DA	neuronal	loss	in	the	aged	fly	brains	when	
compared with controls (Bvr II, 10.37 ± 1.03; Bvr III, 10.70 ±	0.67;	and	control,	11.77	±	0.42).	n	>	20	for	each	data	point.	(f)	Progressive	
elevation	of	Brm	protein	levels	(GFP	signal)	in	the	brains	of	four	PD	model	flies	in	comparison	to	the	control.	Representative	whole-mount	
fluorescence	images	of	fly	brains	are	provided,	with	quantifications	of	the	Brm	protein	level	in	young	(3-day-old),	middle-age	(15-day-old),	
and	aged	(30-day-old)	flies	shown	below	(n >	5).	*indicates	Mann–Whitney	p < 0.01. Scale bar, 10 μm
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or	 LRRK2	 (I1915T)	 led	 to	 significantly	 shortened	median	 life	 span	
of Drosophila	without	affecting	 the	maximal	 life	 span	 (Figure	3c–f,	
Table	S4).	Remarkably,	when	Brm	was	downregulated	specifically	in	
the	DA	neurons	of	PD	model	flies,	the	shortening	of	the	median	life	
span of both female and male Drosophila	was	prevented	(Figure	3c–f,	
Table	S4),	while	overactivation	of	Brm	did	not	exhibit	discernible	ef-
fect	(Figure	3c–f,	Table	S4),	implicating	that	proper	Brm	levels	might	
be crucial in healthy aging.
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2.5 | Genetic manipulations of Brm or BVR modulated 
DA degeneration in multiple Drosophila PD models














RNAi	 did	 not	 mitigate	 the	 degeneration	 (Figure	 4e–h	 and	 Figure	
S9b).	Importantly,	the	aggravation	caused	by	dBVR	overexpression	
could be fully rescued through the addition of BrmDN in all four PD 
model	 flies	 and	 in	 three	 PD	models	 (except	 the	PINK1 deficiency 
model)	 through	Brm	RNAi	 (Figure	 4e–h).	 The	 rescuing	 effect	was	
not	owing	to	titration	of	UAS-mediated	overexpression	(Figure	S3).	
Collectively, these results demonstrated that inactivation of Brm 
protects	DA	neurons	from	age-dependent	degeneration	in	a	variety	
of pathogenic genetic backgrounds.




the female flies in α-synuclein-mediated	PD	model,	while	over-activation	of	Brm	did	not	have	an	aggravating	effect.	Note	that	the	life	span	
of male flies with α-synuclein	overexpression	was	relatively	normal.	(e,	f)	Down-regulation	of	Brm	suppressed	the	shortening	of	the	median	
life	span	of	both	female	and	male	flies	in	LRRK2-mediated	PD	model;	in	contrast,	over-activation	of	Brm	did	not	have	discernible	impacts
     |  7 of 15SUN et al.




Overexpression	of	dBVR	aggravated	the	progressive	DA	neuronal	loss	in	aged	four	PD	model	flies	(αSyn, 8.31 ± 1.01; Lrrk2, 7.89 ± 0.90; 
Pink1 mut, 8.42 ±	1.00;	and	Parkin	RNAi,	8.58	±	1.00),	which	could	be	suppressed	by	MEK	RNAi	or	Aopwt	overexpression	in	all	four	PD	




provided	in	the	Appendix	S2.	*indicates	Mann–Whitney	p <	0.05,	**indicates	p < 0.01. NS, not significant. Scale bar, 10 μm
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2.6 | Prolonged over-activated MEK-ERK-ETS 
signaling in multiple PD fly models
We	then	investigated	the	possible	mechanisms	through	which	Brm	
and	 dBVR	 could	 affect	 DA	 degeneration.	 An	 Ingenuity	 Pathway	
Analysis	(IPA)	revealed	the	connection	of	SMARCA4/Brm	with	ERK	
signaling	pathway	(Figure	1b),	as	was	supported	by	a	previous	study	
(Herr	 et	 al.,	 2010).	On	 the	 other	 hand,	 hBVR	has	 been	previously	
suggested	as	an	ERK	activator	in	HEK293A	cells	(Lerner-Marmarosh,	
Miralem,	Gibbs,	&	Maines,	2008).	Activator	Pointless	 (Pnt)	 and	 re-
pressor Anterior open	 (Aop)	 are	 two	 downstream	 antagonizing	
players	of	the	MEK-ERK	signaling	and	both	belong	to	E-twenty	six	
transcription	factors	(O'Neill,	Rebay,	Tjian,	&	Rubin,	1994).	We	used	
the	 reporter	 fly	 line	 of	 Pnt::EGFP	 (O'Neill	 et	 al.,	 1994)	 to	monitor	
the	MEK-ERK	activity	in	the	fly	brain	and	found	that	both	Brm	RNAi	
and	 dBVR	 RNAi	 resulted	 in	 reduced	 MEK-ERK	 activity	 in	 fly	 DA	
neurons,	while	overexpressing	either	Brm	or	dBVR	upregulated	the	
signaling	(Figure	4i–n).	Conversely,	DA	neuron-specific	knockdown	
of Drosophila MEK (Dsor1)	by	RNAi	(Slack	et	al.,	2015)	or	overexpres-







We	 then	 examined	 whether	 overactivation	 of	 ERK-ETS	 was	




2.7 | Attenuation of MEK-ERK-ETS activation 
prevented DA degeneration in multiple Drosophila 
PD models
We	next	examined	whether	directly	reducing	MEK-ERK-ETS	activa-
tion	was	 sufficient	 to	prevent	 those	common	 forms	of	DA	degen-
eration.	MEK	 RNAi	 fully	 rescued	 PPL1	DA	 neuronal	 loss	 in	 three	
30-day-old	 PD	 model	 flies	 (Figure	 5f–i,	 Figure	 S11a,b),	 and	 the	
rescue	 was	 not	 owing	 to	 titration	 of	 UAS-mediated	 overexpres-
sion	(Figure	S3).	In	contrast,	Drosophila ERK (rolled or rl)	RNAi	(Slack	
et	al.,	2015)	exerted	no	apparent	rescuing	effects,	suggesting	that	it	
was	the	activated	fraction	of	ERK	(pERK),	not	the	abundance	of	the	
ERK	protein,	 that	caused	 the	neurotoxicity.	 In	parallel,	when	MEK	
RNAi	 or	 ERK	RNAi	was	 induced	 alone	 specifically	 in	DA	neurons,	
no	changes	in	the	PPL1	DA	neurons	were	observed	when	compared	
with	age-matched	controls,	suggesting	that	the	rescuing	effects	of	




led	 to	 early	 lethality	 before	 eclosion	 too.	 In	 addition,	DA	neuron-
specific	RNAi	knockdown	of	Pnt	(Slack	et	al.,	2015)	led	to	a	rescue	
or	 mitigation.	 Remarkably,	 DA	 neuron-specific	 overexpression	 of	
the negative regulator, Aop[wt],	completely	blocked	the	aging-related	
PPL1	DA	neuronal	 loss	 in	all	 four	PD	model	 flies	 (Figure	5j–m	and	
Figure	S12a,c),	 and	 the	 rescue	was	not	owing	 to	 titration	of	UAS-




to	early	 lethality	before	eclosion,	 and	overexpression	of	Aop[wt] or 
Aop	 RNAi	 alone	 resulted	 in	 mild	 DA	 neuronal	 loss	 (Figure	 S11a).	




2.8 | Pharmacological inhibition of ERK signaling 
suppresses DA neuronal loss in multiple Drosophila 
PD models
To	 examine	 the	MEK/ERK	 signaling	 pathway	 as	 a	 drug	 target	 for	
intervening	 in	DA	degeneration,	we	started	with	the	MEK1	inhibi-




in	 all	 four	 PD	 fly	 models	 (Figure	 5n).	 Exposure	 to	 another	MEK1	
F I G U R E  5  Attenuation	of	MEK-ERK-ETS	signaling	activity	prevented	dopaminergic	(DA)	degeneration	in	Drosophila.	(a,	b)	The	ERK	







all four PD fly models: αSyn, 11.25 ±	0.89	(j);	Lrrk2,	11.1	±	0.88	(k);	Parkin	RNAi,	11.33	±	0.72	(l);	Pink1	mut,	11.17	±	0.83	(m);	and	control,	
11.53 ±	0.32.	(n–p)	Oral	administration	of	three	MEK	inhibitors	suppressed	DA	degeneration	in	Drosophila, respectively. Two concentrations 
of	either	U0126	(n)	(low	[L]:	1	μg/ml;	high	[H]:	10	μg/ml),	PD0325901	(o)	(L:	1	μg/ml; H: 10 μg/ml),	or	Trametinib	(p)	(L:	1.6	μM;	H:	16	μM)	
were applied (n >	20).	The	genotypes	of	experimental	flies	are	provided	in	the	Appendix	S2.	*indicates	Mann–Whitney	p <	0.05,	**indicates	
p < 0.01. NS, not significant. Scale bar, 10 μm
     |  9 of 15SUN et al.
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Sakai,	2011).	With	 the	optimal	 feeding	concentration	of	16	μM of 
Trametinib	 (Figure	 S12c,d)	 (Slack	 et	 al.,	 2015),	 PPL1	 DA	 neurons	
were	fully	protected	from	degeneration	(Figure	5p).	No	global	brain	
or motor behavioral abnormalities were detected with all these drug 
treatments.	Taken	together,	our	data	demonstrated	that	 the	MEK-
ERK	pathway	could	be	a	valid	drug	target	to	revert	DA	degeneration	
and illustrated that oral administration could be a promising pharma-
cological intervention.
2.9 | Knockdown of SMARCA4 or drug inhibition of 
ERK activity ameliorated mitochondrial defects in 
PINK1-deficient human cells
In humans, PINK1-deficiency	leads	to	mitochondrial	defects	(Bueno	
et	 al.,	 2015).	 To	 determine	whether	 our	 findings	were	 relevant	 to	
human	pathology,	we	first	used	human	SH-SY5Y	cells	to	examined	
the potential impact of SMARCA4 on PINK1 depletion. Lower mito-
chondrial contents and more fragmentated mitochondrial network 
were observed in the PINK1	 RNAi-treated	 SH-SY5Y	 cells.	 While	
SMARCA4	 RNAi	 alone	 did	 not	 significantly	 perturb	 the	mitochon-
drial content and morphology, the genetic manipulation ameliorated 
the mitochondrial abnormality caused by PINK1	RNAi	(Figure	6a,b),	
which was in line with our previous results in Drosophila, implicating 
the	potential	conserved	role	of	SMARCA4	in	the	dopaminergic	neu-
rons. Furthermore, we generated a PINK1−/− HeLa cell line, using the 
CRISPR/Cas9	 technology	 (Figure	 6c)	 (Mali	 et	 al.,	 2013).	 Enhanced	
phosphorylation of ERK and MEK1 was observed in the PINK1−/− 
HeLa	 cells,	 indicating	 an	 aberrant	MAPK	 signaling	 over-activation	
(Figure	 6d).	 Treatment	 with	 the	 MEK1	 inhibitor,	 PD0325901,	 ef-
fectively mitigated multiple mitochondrial defects in the PINK1−/− 
cells, such as reduced mitochondrial membrane potential, lowered 
mitochondrial contents, and abnormal network interconnectivity 
(Figure	6e,f).	In	agreement	with	our	results,	MEK1	inhibitor	has	been	
shown	to	reverse	PD-associated	phenotypes	induced	by	pathologi-




which were highly enriched in aging and neural disorders. The roles 
of	two	candidate	genes	SMARCA4/Brm	and	BLVRA/BVR	were	vali-
dated	 in	 vivo.	The	activity	of	ERK-ETS	 signaling,	 as	 a	 common	ef-
fector	for	SMARCA4/Brm	and	BVR,	was	found	to	be	also	elevated	
in different genetic forms of Drosophila PD models. Thus, we have 
discovered a potential convergent PD pathogenesis pathway. Our 
finding also underscores the important role of epigenetic regula-
tors	and	reveals	a	novel	epigenetic	target	besides	HDACs	and	DNA	
methyltransferases	 (DNMTs)	 for	 the	 therapeutic	 interventions	 of	
aging-related	 disorders,	 including	 PD.	 Remarkably,	 the	 in	 vivo	 ge-
netic manipulations in our studies were specifically restricted in the 
dopaminergic	neurons	 thanks	 to	 the	GAL4-UAS	binary	expression	
system in Drosophila, highlighting the cell autonomous impacts of 
the target genes. In fact, genetic modifications of vulnerable dopa-
minergic neurons per se may be valuable for cell/genetic therapy in 
PD patients in the future.
Brm was found here to be progressively upregulated in the aging 
brains of PD fly models. One possibility is through a genetic imprint-
ing response to elevated calcium level triggered by aberrant neuronal 
activities	or	calcium	metabolism	(Zhang	et	al.,	2016).	Alternatively,	
Brm	could	be	activated	through	NF-kB	mediated	 inflammatory	re-
sponses that are well recognized in the development of neurodegen-
erative	diseases	 (Bonnay	et	al.,	2014).	Besides,	 there	 is	a	clue	that	
Brm functions downstream of Hippo pathway and plays an import-
ant	role	in	a	feedback	loop	between	Crumb	and	Yorkie	in	this	path-
way	(Zhu	et	al.,	2015).	On	the	other	hand,	in	our	unpublished	data,	
F I G U R E  6   Knockdown of SMARCA4	or	drug	inhibition	of	MEK-ERK	signaling	ameliorated	mitochondrial	defects	in	the	PINK1 deficient 
human	cells.	(a)	Knockdown	of	SMARCA4 and PINK1	by	RNAi	in	SH-SY5Y	cells.	Cells	were	transfected	with	interference	dsRNAs	of	PINK1, 
interference	dsRNAs	of	SMARCA4,	interference	dsRNAs	of	PINK1 and SMARCA4,	respectively,	interference	dsRNAs	of	Luciferase	were	
transfected	as	RNAi	control.	Relative	expression	of	PINK1 and SMARCA4 were quantified, at least 3 repeats per column were calculated. 
Scale bars, 10 μm.	(b)	SMARCA4 knock down significantly mitigated the aberrant mitochondrial content and interconnectivity caused 
by PINK1	RNAi	SH-SY5Y	cells.	Mitochondria	were	stained	with	MitoTracker-Red.	The	mean	mitochondrial	content	and	mitochondrial	
interconnectivity	index	(Area/Perim)	are	shown	as	mean	± SD.	*:	indicates	Mann–Whitney	p <	0.05,	**:	indicates	p < 0.01. NS, not 
significant. Scale bars, 10 μm.	(c)	CRISPR/Cas9	to	establish	the	PINK1−/− HeLa cell line. Schematic overview of the strategy used to generate 
the pink1	knockout	allele,	Sanger	sequencing	was	used	to	identify	the	targeted	mutations,	and	Western	blot	analysis	verified	the	loss	
of PINK1 protein. Control or PINK1	KO	HeLa	cells,	untreated	(-)	or	treated	(+)	with	the	protonophore	m-chlorophenylhydrazone	(CCCP)	
were	used;	CCCP	was	used	to	prevent	PINK1	protein	from	degradation	(Narendra	et	al.,	2010).	(d)	Over-activated	MEK/ERK	signaling	
in PINK1−/−	HeLa	cells.	(e)	Inhibition	of	MEK-ERK	signaling	by	PD0325901	rescued	mitochondrial	membrane	potential	(MMP)	defects	in	
PINK1−/−	HeLa	cells.	The	mean	ratio	of	the	JC-1	dye	intensity	in	red	channel	to	green	channel	is	shown	as	mean	± SD to quantify MMP. 
Relative MMP between PINK1−/−	and	control	is	also	shown.	(f)	Inhibition	of	MEK/ERK	signaling	improved	mitochondrial	content	and	
mitochondrial interconnectivity in PINK1−/−	HeLa	cells.	Mitochondria	were	stained	with	MitoTracker-Red.	The	mean	mitochondrial	content	
and	mitochondrial	interconnectivity	index	(Area/Perim)	are	shown	as	mean	± SD. The drug solvent used was DMSO, and equivalent amounts 
of	DMSO	were	used	in	parallel	to	the	drug	as	a	treatment	control.	Representative	confocal	images	and	quantifications	are	shown.	*indicates	
Mann–Whitney	p <	0.05,	**indicates	p <	0.01,	***indicates	p < 0.001. NS, not significant. Scale bars, 10 μm.	(g)	A	mechanistic	model	of	the	
signaling loop in normal aging and PD pathogenesis is proposed, and the potential drug intervening points are illustrated
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we	did	observe	the	differential	expression	of	other	oxidoreductases	
(e.g.,	 P450,	 sulfiredoxin,	 and	 phenoloxidase)	 at	 the	 early-middle	
stage of PD. Therefore, it remains possible that Brm might directly 
interact with Keap1/Nrf to elicit a program of sequential cellular re-
sponses	to	oxidative	stress	in	DA	neurons.
Inactivation of Brm was shown here to prevent dopaminergic 
neurons from degeneration. One putative route was through modu-
lating	the	MAPK/ERK	signally	activity.	Accordingly,	Brm	was	shown	
to	 directly	 interact	 with	 Dsor1	 (MEK1)	 and	 promotes	 EGFR-Ras-
MAPK	 signaling	 activity	 (Friedman	 et	 al.,	 2011;	Herr	 et	 al.,	 2010).	
Nevertheless, the possibility could not be ruled out that direct inter-
actions	exist	between	Brm	with	transcriptional	factors	downstream	
of	MAPK/ERK	 signaling,	 such	 as	 Pnt	 or	 Aop,	 constituting	 a	 posi-
tive	 auto-regulation	 feedback	 loop.	 Alternative	mechanisms	 await	
further investigation to elucidate the effects of Brm.
Our	 finding	 that	 Brm	 inactivation	 protects	 DA	 degeneration	
seems to be at odds with the positive roles of Brm in the neural de-
velopment (De Rubeis et al., 2014; Koga et al., 2009; Zhang et al., 
2016).	However,	previous	studies	have	shown	SWI/SNF	complexes	





we	did	not	observe	 substantial	 pathogenic	 effect	 by	overexpress-
ing Brm in the Drosophila	 DA	 neurons.	Dosage	 and	 non-linear	 ef-
fect might also contribute to the insufficiency. Nevertheless, future 
works	should	clarify	the	complex	role	of	Brm	in	the	aging	neurons.
On the other hand, we used the String PPI database to search for 
BLVRA	and	SMARCA4,	 and	could	not	 find	any	direct	 interaction	be-






aggravated degenerative phenotypes in multiple PD models, which could 
be remarkably rescued by inactivation of the Drosophila homologue of 
SMARCA4	(Brm).	The	detail	molecular	mechanisms	how	they	act	in	con-





and	 somewhat	 controversial	 (Kautu,	Carrasquilla,	Hicks,	Caldwell,	&	
Caldwell,	2013;	Kim	&	Choi,	2010;	Reinhardt	et	al.,	2013),	very	likely	
owing to the fact that most previous studies were performed in vitro 




Previously, targeted inhibition of ERK signaling was demon-
strated	to	mitigate	spinocerebellar	ataxia	type	1	in	Drosophila and 
mice	 models	 (Park	 et	 al.,	 2013).	 In	 addition,	 direct	 attenuation	
of	MAPK/ERK	was	 shown	 to	be	 sufficient	 to	 extend	 life	 span	of	
Drosophila	 (Slack	 et	 al.,	 2015).	 Indeed,	 three	 compounds	 that	 in-
hibited	MEK-ERK	signaling	also	ameliorated	DA	degeneration	in	all	
PD	fly	models	in	current	studies.	Among	them,	Trametinib,	an	FDA-




ferent	 tissues	or	 cellular	 contexts	might	differentially	 respond	 to	
distinct	 level	of	MAPK/ERK,	and	 the	understanding	of	 the	quan-
titative relationship between ERK signaling and outcomes would 
benefit future efficacy study of ERK inhibitors upon life span and 
age-related	disorders.
To our knowledge, this manuscript represents the first report 
of	compounds	that	are	effective	 in	preventing	DA	degeneration	 in	
vivo in the four most common genetic forms of PD, compared to a 
previous	report	of	Rapamycin	(Tain	et	al.,	2009).	MEK-ERK-ETS	and	
mTOR/4E-BP	 pathways	 might	 converge	 on	 common	 downstream	
effectors such as mitochondrial activity/quality control, proteosta-
sis,	autophagy,	oxidative	stress	response,	DNA	damage	repair,	and	
DNA-chromatin	modifications,	 all	 of	 which	 are	 important	 aspects	
during aging. It is conceivable that cocktail strategies using both lines 
of inhibitors might eventually balance symptoms mitigation and side 
effects. Due to the high degree of evolutionary conservation in the 




4  | E XPERIMENTAL PROCEDURES
4.1 | Frequent gene co-expression analysis
Eleven	 gene	 expression	 datasets	 from	 NCBI	 Gene	 Expression	
Omnibus	 (GEO)	 were	 used:	 GDS2519,	 GDS2821,	 GDS3128,	
GDS3129,	 GSE19587,	 GSE20141,	 GSE20146,	 GSE20153,	
GSE20292, GSE20295, and GSE20333. Detailed bioinformatics 
analysis	is	described	in	Appendix	S1.
4.2 | SNP query method
PD	 gene	 database	 PDGene	 (http://www.pdgene.org)	 was	 used	
(Nalls	et	al.,	2014),	detail	in	the	Appendix	S1.
4.3 | Drosophila Stocks and nomenclature
Fly	genotypes	for	each	experiment	were	listed	in	the	Appendix	S2.	
Detail information of fly strains and husbandry was described in the 
Appendix	S1.





4.5 | Drosophila PD models and pathologic 
phenotype evaluation
At	 least	 20	hemisphere	 brains	were	 quantified	 via	 double-blinded	
fashion for each data point (n >	20),	details	in	the	Appendix	S1.
4.6 | Semi-quantitative RT-PCR and Quantitative 
Real-time PCR
Details	in	the	Appendix	S1.









capto)	 butadiene,	 Selleck	 #S1102),	 PD0325901	 (Selleck	 #S1036)	
or	 Trametinib	 (Selleck	 #S2673)	were	 applied.	 See	 Appendix	 S1	 for	
details.
4.10 | Generation of PINK1 knockout HeLa cell lines 
using CRISPR/Cas9 gene editing
See	Appendix	S1	for	details.
4.11 | Assessment of mitochondrial membrane 
potential (MMP)
Mitochondrial membrane potential was assessed with the probe 
JC-1	(Invitrogen).	See	Appendix	S1	for	details.
4.12 | Assessment of mitochondrial 
content and morphology
The mitochondrial content and morphology were assessed with 
Mito-Morphology	Macro	in	ImageJ	as	previously	described	(Dagda	
et	al.,	2009;	Schneider,	Rasband,	&	Eliceiri,	2012).
4.13 | Genes knockdown in SH-SY5Y cells
Three	 pairs	 of	 siRNAs	 target	 to	 human	 PINK1	 or	 SMARCA4	
were	designed	and	 synthetized.	 SH-SY5Y	cells	were	 transfected	
with	 siRNAs	 to	 perform	mitochondrial	 content	 and	morphology	
analysis.
4.14 | Assessment of whole brain Redox state
The	 CM-H2	 DCFDA	 fluorescein	 dye	 (Invitrogen,	 Cat#	 C400)	 and	
redox-sensitive	GFPs	(roGFPs)	protein,	fly	lines	of	tub-mito-roGFP2	
or	 UAS-roGFP2	 genotype	 were	 employed	 to	 measure	 the	 whole	
brain ROS stress of PD Drosophila.	 (Liu,	Celotto,	Romero,	Wipf,	&	
Palladino,	2012;	Wu,	Cao,	Chang,	&	Juang,	2017).
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